Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
Shionogi will establish a joint venture in Shanghai next month with China’s biggest insurer Ping An Insurance under their strategic partnership deal sealed earlier this year, making the JV the base of its Chinese and Asian operations, the Osaka drug…
To read the full story
Related Article
- Shionogi to Take Full Control of 2 China Joint Ventures
December 24, 2024
- Shionogi’s Chinese JV Commences RWD Collection, Analysis of Metabolic Diseases
July 2, 2021
- Shionogi Chief Says China JV Marks Pivot from Overly US-Focused Investments
October 14, 2020
- Shionogi Hooks Up with China’s Biggest Insurance Group, Eyes RWD-Based Drug Development
March 31, 2020
BUSINESS
- Nippon Kayaku’s Avastin Biosimilar Share Hits 58%
February 3, 2026
- Japan’s 1st OTC Morning-After Pill Now Available
February 3, 2026
- Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
- AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…